A novel model to predict cellular COVID-19 drug targets
Scientists from the United Kingdom have utilized a computational model of a human lung cell to comprehend how coronavirus that causes COVID-19 uses human host cell metabolic processes to replicate. This research aids in comprehending exactly how the virus utilizes the host to survive, and allow to predict about the medications against COVID-19.
An essential step of the lifecycle is the synthesis of the viral particles within the host cell. Comprehending this process is crucial to finding methods to prevent the virus from surviving.
Researchers from the University of Warwick have used a computational model of a human lung cell metabolic process to capture the stoichiometric amino and nucleic acid needs of coronavirus. The outcomes of the research are issued in Life Science Alliance.
Revealing reactions in the central metabolism, along with amino acid and nucleotide biosynthesis pathways, this model has found host-based metabolic perturbations preventing coronavirus replication. Scientists have observed that few of these metabolic perturbations have the ability to hinder virus replication uniquely.
Likewise, scientists have observed that some of the catalyzing enzymes of such reactions have shown interactions with existing medications. This can be utilized for laboratory analysis of the presented predictions utilizing gene knockouts and RNA-interference methods.
A stoichiometric biomass role for the coronavirus was developed and integrated into a human lung cell genome-scale metabolic model, said Professor Orkun Soyer, School of Life Sciences at the University of Warwick.
They later predicted reaction perturbations that can hinder coronavirus replication in common or selectively, without hindering the host metabolism. The anticipated reactions mainly come under glycolysis as well as oxidative phosphorylation pathways and their links to amino acid biosynthesis pathways.
Dr. Hadrien Delattre, the University of Warwick, said that these outcomes reveal the potentiality of targeting the host metabolic process for restraint of coronavirus replication in human cells in common and particularly in human lung cells.
He also stated that further research needs to be performed to understand SARS-CoV-2 infected cells and their metabolic process. However, this model can be utilized as a starting point for testing particular drug predictions.
A novel model to predict cellular COVID-19 drug targets
